Clinical guidelines

• ATIC position statement - Baricitinib treatment in type 1 diabetes

  Following publication of the positive outcomes of the BANDIT trial in NEJM in December 2023, ATIC has received many enquiries about the use of baricitinib for the treatment of type 1 diabetes. The BANDIT team, with support from ATIC’s Community Engagement Panel and Steering Committee, prepared a position statement to provide guidance and inform decision making for health care professionals considering prescribing off-label baricitinib to treat type 1 diabetes. The position statement, along with a community information sheet are available for review and download here:

  Baricitinib position statement

  Community Statement

  Care pathways - monitoring type 1 diabetes

  A group of ATIC clinician-researchers with support from JDRFA have published the Australian guidelines for care pathways for people with early-stage type 1 diabetes. The Australian guidelines were developed concurrently with the international ‘consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes’. The new care pathways, along with the international guidelines are available for review and download here:

  Care pathways for people with early-state type 1 diabetes in Australia

  International consensus guidelines